Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Drug-eluting stent thrombosis.

D H Steinberg1, L F Satler

  • 1Division of Cardiology, Washington Hospital Center, Washington, DC 20010, USA. daniel.h.steinberg@medstar.net

Minerva Cardioangiologica
|April 25, 2008
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Adaptability of Streptococcus thermophilus to Lactose, Glucose and Galactose.

Journal of food protection·2019
Same author

Bacteriocin production by Streptococcus thermophilus in complex growth media.

Biotechnology letters·2016
Same author

Molecular analysis of the glutamate decarboxylase locus in Streptococcus thermophilus ST110.

Journal of industrial microbiology & biotechnology·2012
Same author

Percutaneous approaches to mitral valve regurgitation.

Herz·2011
Same author

IMAGE CARDIO MED: Percutaneous closure of a left ventricular outflow tract pseudoaneurysm causing extrinsic left coronary artery compression by transseptal approach.

Circulation·2010
Same author

Emergence of the concept of platelet reactivity monitoring of response to thienopyridines.

Heart (British Cardiac Society)·2009
Same journal

Mechanistic factors of cardiovascular diseases.

Minerva cardioangiologica·2020
Same journal

Robotic-assisted coronary artery bypass grafting: current knowledge and future perspectives.

Minerva cardioangiologica·2020
Same journal

Features of degenerative mitral valve prolapse in the North East of China: repair characteristics, and short-term follow-up results.

Minerva cardioangiologica·2020
Same journal

Myocardial revascularization in chronic coronary syndromes: does viability matter?

Minerva cardioangiologica·2020
Same journal

Extracorporeal membrane oxygenation for COVID-19: effective weapon or futile effort?

Minerva cardioangiologica·2020
Same journal

Heart and endurance sports: excesses are often unhealthy.

Minerva cardioangiologica·2020
See all related articles

Drug-eluting stents (DES) reduce restenosis but not death or heart attack. Concerns about late stent thrombosis (LST) and very late stent thrombosis (VLST) after stopping antiplatelet therapy warrant careful review.

Area of Science:

  • Cardiology
  • Interventional Cardiology
  • Biomaterials

Background:

  • Drug-eluting stents (DES) significantly reduce restenosis and target lesion revascularization compared to bare metal stents (BMS).
  • Despite restenosis benefits, DES do not decrease rates of death or myocardial infarction.
  • Long-term safety concerns include a potential increase in late stent thrombosis (LST) and very late stent thrombosis (VLST), especially after antiplatelet therapy cessation.

Purpose of the Study:

  • To critically appraise drug-eluting stents (DES) and their role in percutaneous coronary intervention.
  • To focus on the definitions, incidence, mechanisms, and clinical implications of DES thrombosis.
  • To address concerns regarding late and very late stent thrombosis associated with DES.

Main Methods:

Related Experiment Videos

  • Review of existing literature on drug-eluting stent thrombosis.
  • Analysis of factors contributing to DES thrombosis, including patient, lesion, stent, and physician-related elements.
  • Examination of the debated incidence and definitions of DES thrombosis.

    • Main Results:

    • DES are effective in reducing restenosis but offer no survival benefit over BMS.
    • A small but significant risk of LST and VLST exists with DES, particularly after antiplatelet therapy discontinuation.
    • The multifactorial nature of DES thrombosis involves modifiable and non-modifiable factors.

    Conclusions:

    • The benefits of DES are primarily limited to reducing restenosis.
    • Concerns about LST and VLST necessitate a critical evaluation of DES use in percutaneous coronary intervention.
    • Understanding the mechanisms and contributing factors is crucial for managing DES thrombosis.